# DEC - 5 2001

<table><tr><td rowspan="3">Meridian</td><td colspan="2">K112125: illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Description:</td><td>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td>Identification:</td><td>Attachment 002.002</td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 17, 2011</td></tr></table>

# 510(k) number:

# K112125

Submitter: Submitter's address:

Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati, Ohio 45244

Contact: Contact number:

Michelle Smith (513) 271-3700

# Device name:

illumigene® Group B Streptococcus (GBS) illumigene® Group B Streptococcus (GBS) External Control Kit

Common name: Classification name:

Streptococcus spp. Serological reagents   
Nucleic Acid Amplification Assay System, Group B Streptococcus Direct Specimen Test   
NJR, CFR Section 866.3740

# Predicate device:

K062948: Cepheid Smart GBS Model SCGBS-100N-50

# Reference comparator:

Culture enrichment followed by bacterial culture with Group B Streptococcus identification

# Description of the device:

and Detection System.

Tl B DNA amplification occurs in the illumigene GBS Test Device.

Sample results are reported as Positive or Negative based on the detected change in light transmission.

Kit is required for routine Quality Control.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K112125: illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Description:</td><td>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td rowspan="2">Bioscience, Inc.</td><td>Identification:</td><td>Attachment 002.002</td></tr><tr><td>Date:</td><td>November 17, 2011</td></tr></table>

# Intended Use:

T i Broth or TransVag Broth.

The illuigene assutilis loo-ediate isothermal DA mplifiation $( \mathsf { L A M P } ) ^ { 1 , 2 }$ technology to detect Streptococcus testing as recommended for penicillin-allergic women.

or point-of-care use.

# Comparison to predicate device:

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>illumigene® GBS            x             2</td><td rowspan=1 colspan=1>Cepheid® Smart GBS</td></tr><tr><td rowspan=1 colspan=1>Test Format</td><td rowspan=1 colspan=1>DNA Amplification Assay</td><td rowspan=1 colspan=1>DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=3>Intended Use</td></tr><tr><td rowspan=1 colspan=1>DNA Amplification Technology</td><td rowspan=1 colspan=1>Loop-Mediated Isothermal Amplification (LAMP)</td><td rowspan=1 colspan=1>Real-Time Polymerase Chain Reaction (PCR)</td></tr><tr><td rowspan=1 colspan=1>Target Sequences Detected</td><td rowspan=1 colspan=1>213 base pair (bp) sequence residing in the 593-805 bp region of S. agalactiae genomeSegment 3</td><td rowspan=1 colspan=1>Unique region of the S.agalactiae chromosome</td></tr><tr><td rowspan=1 colspan=1>Qualitative/Quantitative</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Screening, Diagnostic or IdentificationTest</td><td rowspan=1 colspan=1>Diagnostic</td><td rowspan=1 colspan=1>Diagnostic</td></tr><tr><td rowspan=1 colspan=3>Specimen Types</td></tr><tr><td rowspan=1 colspan=1>Vaginal/Rectal Swab Specimen</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>Yes (Direct Method)</td></tr><tr><td rowspan=1 colspan=1>Vaginal/Rectal Swab SpecimenEnriched in Lim Broth</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes (Enriched Method)</td></tr><tr><td rowspan=1 colspan=1>Vaginal/Rectal Swab SpecimenEnriched in TransVag Broth</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Reagents/Components</td><td rowspan=1 colspan=1>illumigene Control Reagentillumigene Reaction Bufferillumigene GBS Test Deviceillumigene Heat Treatment Tubes</td><td rowspan=1 colspan=1>Sample Preparation ReagentTreatment ReagentLysis ReagentMaster MixPositive ControlNegative Control</td></tr></table>

<table><tr><td rowspan=5 colspan=3>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>K112125: illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Identification:</td><td rowspan=2 colspan=1>Attachment 002.002</td></tr><tr><td rowspan=2 colspan=2>Bioscience, Inc.</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 17, 2011</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>illumigene GBS</td><td rowspan=1 colspan=1>Cepheid® Smart GBS</td></tr><tr><td rowspan=1 colspan=1>Extraction</td><td rowspan=1 colspan=1>Not applicable. Sample preparation by heattreatment. DNA extraction and purification notrequired.</td><td rowspan=1 colspan=1>Self-contained and automated</td></tr><tr><td rowspan=1 colspan=1>Amplification</td><td rowspan=1 colspan=1>Self-contained and automated</td><td rowspan=1 colspan=1>Self-contained and automated</td></tr><tr><td rowspan=1 colspan=1>Detection</td><td rowspan=1 colspan=1>Self-contained and automated</td><td rowspan=1 colspan=1>Self-contained and automated</td></tr><tr><td rowspan=1 colspan=1>Testing Time</td><td rowspan=1 colspan=1>Approximately 60 minutes</td><td rowspan=1 colspan=1>Approximately 75 minutes</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Not required</td><td rowspan=1 colspan=1>Not required</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self-contained and automated</td><td colspan="1" rowspan="1">Self-contained and automated</td></tr><tr><td colspan="1" rowspan="1">Testing Time</td><td colspan="1" rowspan="1">Approximately 60 minutes</td><td colspan="1" rowspan="1">Approximately 75 minutes</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Not required</td><td colspan="1" rowspan="1">Not required</td></tr><tr><td colspan="3" rowspan="1">Controls</td></tr><tr><td colspan="1" rowspan="1">Inhibition, Assay</td><td colspan="1" rowspan="1">Providedillumigene Control Reagent: Non-infectiousPlasmid DNA, S. aureus insertillumigene GBS Test Device, Control Chamber:Staphylococcus aureus LAMP Primers</td><td colspan="1" rowspan="1">ProvidedMaster Mix: Internal control DNA templatePositive Control: Internal Control DNA template,non-infectious genomic GBS DNANegative Control: Internal Control DNA template,non-infectious genomic DNA from Streptococcuspneumoniae</td></tr><tr><td colspan="1" rowspan="1">External</td><td colspan="1" rowspan="1">Adjunct Reagentsillumigene Group B Streptococcus (GBS)External Control Kit, Catalog 279900</td><td colspan="1" rowspan="1">User SuppliedKWIK-STIK Cepheid: Smart GBS QC Set fromMicroBioLogics, catalog 8165; one each ofStreptococcus agalactiae low- , moderate- and high-level positive control and L. acidophilus as negativecontrol.</td></tr><tr><td colspan="1" rowspan="1">Extraction</td><td colspan="1" rowspan="1">Not ApplicableSample preparation, including heat treatmentmonitored by external thermometer andinterval timer. Equipment is user supplied.</td><td colspan="1" rowspan="1">User Supplied</td></tr><tr><td colspan="3" rowspan="1">Equipment</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">illumipro-10™" Automated IsothermalAmplification and Detection System</td><td colspan="1" rowspan="1">SmartCycler Dx System</td></tr><tr><td colspan="1" rowspan="1">General Laboratory Equipment</td><td colspan="1" rowspan="1">Micropipette 50 μL, 200 μLDry-bath with 12 mm heat block, 95 CDigital Thermometer with Max/MinTemperature MemoryInterval TimerVortex Mixer</td><td colspan="1" rowspan="1">Vortex Mixer with microtube holderMicrocentrifugeMicropipettors, 5 - 1000 μL rangeCooling Block, 2 - 8 CStopwatch or timer</td></tr><tr><td colspan="1" rowspan="1">Reading Method</td><td colspan="1" rowspan="1">Visible Light Transmission</td><td colspan="1" rowspan="1">Fluorescence</td></tr><tr><td rowspan="3">Meridian</td><td colspan="2">K112125: ilumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Description:</td><td>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td>Identification:</td><td>Attachment 002.002</td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 17, 2011</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic   ,&quot;</td><td rowspan=1 colspan=1>illumigene® GBS             .</td><td rowspan=1 colspan=1>Cepheid® Smart GBS</td></tr><tr><td rowspan=1 colspan=3>Results</td></tr><tr><td rowspan=1 colspan=1>Group B Streptococcus SerotypesTested</td><td rowspan=1 colspan=1>a , I  </td><td rowspan=1 colspan=1> I I  V</td></tr><tr><td rowspan=1 colspan=1>Results Interpretation</td><td rowspan=1 colspan=1>INVALIDPOSITIVENEGATIVE</td><td rowspan=1 colspan=1>POSITIVENEGATIVEINVALIDND (Not Determined)NO RESULT</td></tr><tr><td rowspan=1 colspan=3>Performance</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>97.4% [95% CI: 91.9% - 99.0%]</td><td rowspan=1 colspan=1>98.7% [95% CI: 92.8% - 100.0%]</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>92.3% [95% CI: 90.0% - 94.1%]</td><td rowspan=1 colspan=1>90.4% [95% CI: 85.8% - 93.9%]</td></tr></table>

# Performance Comparison, Non-clinical Tests:

# Interference Testing

Selp $2 . 5 \%$ v/v or in place of the potentially cross-eactive organiss.Each inoculated sample was tested in tripliate.

Streptococcus test results: Amniotic fluid $( 1 0 \% \ v / v )$ , Human DNA (100 ng/Test), Urine $( 3 0 \% v / v )$ ,Whole Blood $( 2 . 5 \% \ v / v )$ . The following substances do not interfere with test results: Meconium, Stool, Hemorrhoidal cream $\{ 3 0 . 6 5 ~ \mathrm { m g } / 1 0 0 \mathrm { m g } \}$ , Miconazole (fungicide), Mucin $( 0 . 5 { - } 1 . 5 \% )$ , Spermicidal gel (nonoxynol 9) (4 mg/100mg). Lubricating gel produced False Negative Results in 1 of greater than $2 . 5 \%$ v/v interferes with the illumigene GBS assay.

# Cross-reactivity Study

C/ triplicate. Cross-reactivity with Enterococcus dispar was observed in one of seven replicates tested.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>K112125: illumigene Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002.002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 17, 2011</td></tr></table>

T CCC Clostridium eptcu,ClostdiumsorllClostdium sporgenes,Clostdium tetanCorynebacerum ge Co Ei acLglahia,aeorelaoanelaoran isiago, Pepteptooccusanobs,Pesoashiglloide,pronasasaccarolyarevotlamean, SrecocuStcrecetcu oe,reccs, Echovirus, Epstein Barr virus, Herpes Simplex Virus-1, Herpes Simplex Virus-2, Rotavirus.

$\times 1 0 ^ { 6 }$ and $9 . 9 \times 1 0 ^ { 6 }$ CFU/mL with no reacion with the illumiene GBS assay.

# Performance Comparison, Clinical Tests:

Broth prior to illumigene testing. Four hundred three (403, $4 8 . 8 \%$ specimens were enriched with Lim Broth and 423 $( 5 1 . 2 \% )$ years of age, with age unknown for 3 $\{ 0 . 4 \% \}$ of the patient population. No differences in test performance were observed based on enrichment medium or patient age. Overall assay Sensitivity is reported as $9 7 . 4 \%$ c $9 5 \%$ CI: $9 1 . 9 \% - 9 9 . 0 \%$ where Specificity is $9 2 . 3 \%$ $1 9 5 \%$ CI: $9 0 . 0 9 6 - 9 4 . 1 \% 1$ Tab 1 shows assay hows overal assay performance, including evaluation by enrichment medium; Table2 summarizes assay performance by Clinical Site.

Table 1: Performance characteristics summary   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=3>Positive Samples·:</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigenelCulture</td><td rowspan=1 colspan=1>% Sensitivity    </td><td rowspan=1 colspan=1>:        · ::95% CIL  </td><td rowspan=1 colspan=1>illumigene/Culturestia</td><td rowspan=1 colspan=1>HA% Specificityidis.   </td><td rowspan=1 colspan=1>        295% CI...</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>150/154</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>91.9 - 99.0%</td><td rowspan=1 colspan=1>610/661</td><td rowspan=1 colspan=1>92.3%</td><td rowspan=1 colspan=1>90.0 - 94.1%</td></tr><tr><td rowspan=1 colspan=1>Lim</td><td rowspan=1 colspan=1>82/84</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>91.7 - 99.3%</td><td rowspan=1 colspan=1>296/315</td><td rowspan=1 colspan=1>94.0%</td><td rowspan=1 colspan=1>90.8 - 96.1%</td></tr><tr><td rowspan=1 colspan=1>TransVag</td><td rowspan=1 colspan=1>68/70</td><td rowspan=1 colspan=1>97.1%</td><td rowspan=1 colspan=1>90.2-99.2%</td><td rowspan=1 colspan=1>314/346</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>87.2 - 93.4%</td></tr></table>

Table 2: Performance characteristics summary   

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>K112125: ilumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 002.002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>November 17, 2011</td></tr></table>

<table><tr><td rowspan=2 colspan=1>SiteIdentification</td><td rowspan=2 colspan=1>EnrichmentBroth</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigene/Culture</td><td rowspan=1 colspan=1>%Sensitivity</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigene/Culture</td><td rowspan=1 colspan=1>%Specificity</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>TransVag</td><td rowspan=1 colspan=1>32/33</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>84.7-99.5%</td><td rowspan=1 colspan=1>197/199</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.4 - 99.7%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>TransVag</td><td rowspan=1 colspan=1>36/37</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=1>86.2 - 99.5%</td><td rowspan=1 colspan=1>117/147</td><td rowspan=1 colspan=1>79.6%</td><td rowspan=1 colspan=1>72.4 -85.3%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Lim</td><td rowspan=1 colspan=1>38/39</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>86.8 - 99.5%</td><td rowspan=1 colspan=1>162/168</td><td rowspan=1 colspan=1>96.4%</td><td rowspan=1 colspan=1>92.4-98.4%</td></tr><tr><td rowspan=1 colspan=1>Site 4.</td><td rowspan=1 colspan=1>Lim</td><td rowspan=1 colspan=1>44/45</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>88.4 -99.6%</td><td rowspan=1 colspan=1>134/147</td><td rowspan=1 colspan=1>97.8%</td><td rowspan=1 colspan=1>85.5 - 94.8%</td></tr></table>

Invalid results were obtained for $\mathtt { 1 1 } / 8 2 6$ samples tested or $1 . 3 \%$ .Two of the 11 samples remained invalid after repeat testing of the al  . Concordant result testing showed a combined correlation between molecular methods of $9 7 . 7 \%$ .

# Analytical Sensitivity

probability (eg, $9 5 \%$ i v below:

<table><tr><td rowspan=1 colspan=1>Serotype</td><td rowspan=1 colspan=1>Streptococcus agalactiae StrainDescription</td><td rowspan=1 colspan=1>CFU/Test</td></tr><tr><td rowspan=1 colspan=1>la</td><td rowspan=1 colspan=1>NCTC 11248</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>lb</td><td rowspan=1 colspan=1>ATCC 12401</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Ic</td><td rowspan=1 colspan=1>NCTC 11253</td><td rowspan=1 colspan=1>640</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11/2</td><td rowspan=1 colspan=1>320</td></tr><tr><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>ATCC 12403</td><td rowspan=1 colspan=1>160</td></tr><tr><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>ATCC BAA-611</td><td rowspan=1 colspan=1>1280</td></tr></table>

Serotype X: NCTC 11249; Unknown Serotype: ATCC 13813 and ATCC12386.

# Reproducibility

samples (i.e. limit of detection, $n = 3$ )'and high negative samples $( n = 3 )$ . The panels also included contrived positive $( n = 3 )$ samples and natural negative samples $( n = 1 )$ .Testing was performed by different operators at each site on the same day (intra-assay study. The results are given in the table below:

<table><tr><td rowspan="3">Meridian</td><td colspan="2">K112125:illumigene® Group B Streptococcus (GBS) DNA Amplification Assay</td></tr><tr><td>Description:</td><td>illumigene® GBS 510(k) Summary Statement</td></tr><tr><td>Identification:</td><td>Attachment 002.002</td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>November 17, 2011</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 4</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr></table>

# Conclusions

T Broth. The test is diagnostic for Group B Streptococcus.

Meridian Bioscience, Inc. c/o Susan D. Rolih Director Quality Systems 3471 River Hills Drive Cincinnati, OH 45244

Re: K112125 Trade/Device Name: illumigene ® Group B Streptococcus (GBS) DNA Amplification Assay Regulation Number: 21 CFR $\$ 866.3740$ Regulation Name: Nucleic acid amplification assay system Regulatory Class: Class I Product Codes: NJR Dated: November 17, 2011 Received: November 18, 2011

Dear Ms. Rolih:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice

requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Valy Cp

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Devices   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication(s) for Use Form

510(k) Number if known): 112125

Device Name: illumigene Group B Streptococcus (GBS) DNA Amplification Assay

# Indications for Use:

The illumigene Group B Streptococcus (GBS) assay, performed on the illumipro- ${ \bf { 1 0 ^ { \dprime } } } ^ { \dprime \dprime }$ , is a qualitative in vitro diagnostic u antepartum women. Enriched cultures are obtained by $1 8 - 2 4$ hour incubation of vaginal/rectal swab specimens in selective broth medium, either Lim Broth [Todd Hewitt Broth supplemented with colistin $( 1 0 \mu \ Z / m L )$ and nalidixic acid $\lbrace 1 5 \mu \mathbf { g } / \mathbf { m } \mathbf { L } \rbrace ]$ or TransVag Broth [Todd-Hewitt broth supplemented with gentamycin $( 8 \mu \geq / m L )$ and nalidixic acid (15 $\mu \mathbf { { g } } / \mathsf { m } \nu ]$ .

The illuigene GBS assay utilizes loop-mediated isothermal DNA amplifiation (LAMP) technology t detect intended to diagnose or monitor treatment for GBS infections.

Teille   s ot pov ustbiy sul.Cullat ee  pe susceptibility testing as recommended for penicillin-allergic women.

not intended for point-of-care use.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/cf46d951a8b204e0cb55ce29c94d1710392036009206fdd7caa874fb8f30eabe.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

![](images/47a297242ec877fa23aff1b36f91cda6ca35ae8887f367dea230aa8e3221d578.jpg)